secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001493152-25-009731
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics reports preclinical data: systemic RTNova platform delivers gene therapy payload to tumors
--------------------------------------------------------------------------------

- RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.
- Single dose of 3KO RT with immunotherapeutic payload increased leukocyte infiltration to 92% vs 46% untreated.
- Complete eradication of certain tumors observed in preclinical model after treatment with 3KO RT plus payload.
- Platform also acts as a viral vector to express therapeutic genes at tumor sites; potential partnerships noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225009731/0001493152-25-009731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225009731/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer